First Tracks Biotherapeutics, Inc. quarterly report, Q3 FY2026

First Tracks Biotherapeutics, Inc. — Form 10-Q Summary

Reporting period: Quarter ended September 30, 2026; filed November 3, 2026. First Tracks is a clinical-stage biotechnology company developing antibody therapies for autoimmune and inflammatory diseases. Its pipeline includes ANB033, rosnilimab and ANB101. The company has no approved products and reports no product revenue.

Financial performance and position

Amounts below are in millions of dollars except per-share data. Operating margins are not meaningful because the company has no revenue.

MetricQ3 2026Q3 2025Nine months 2026Nine months 2025
RevenueNoneNoneNoneNone
Research and development expense$23.8$33.3$83.4$114.1
General and administrative expense$9.0$11.7$37.1$28.2
Total operating expenses / operating loss$32.8$45.1$120.6$142.2
Interest income$1.5$3.2$5.4$10.8
Net loss$31.4$41.9$115.2$131.5
Basic and diluted loss per share$0.88$1.50$3.25$4.52
  • Q3 R&D expense declined $9.5 million year over year, mainly from lower clinical and related costs. Nine-month R&D declined $30.6 million, largely due to lower clinical costs, including reduced rosnilimab spending.
  • Q3 G&A expense decreased $2.7 million year over year. Nine-month G&A increased $9.0 million, reflecting higher stock compensation, personnel and legal expenses.
  • Cash and cash equivalents were $155.6 million at September 30, 2026, versus $238.2 million at December 31, 2025. There were no available-for-sale investments at September 30; year-end 2025 short-term investments were $73.4 million. Current assets were $165.7 million and current liabilities $18.1 million.
  • Operating cash use was $81.5 million for the first nine months, compared with $114.3 million in the 2025 period. Investing activities provided $35.0 million, primarily from investment maturities; financing activities used $36.0 million. Cash declined by $82.6 million.
  • The filing reports no debt. Operating lease liabilities totaled approximately $3.8 million, including $2.4 million current. Stockholders’ equity was $151.0 million.

Comparability and material changes

The Spin-Off from AnaptysBio was completed April 20, 2026, and First Tracks began trading as TRAX that day. The 2026 nine-month results combine carve-out results through April 19 with standalone results thereafter; 2025 results are carve-out results. Q3 2026 is standalone, while Q3 2025 is carve-out. Historical allocations and centralized funding from AnaptysBio may not represent the costs or financing First Tracks would have incurred as a standalone company, so period comparisons require caution.

In the Spin-Off, AnaptysBio distributed approximately 29.1 million shares and allocated $100 million in cash to First Tracks. The April private placement generated approximately $80 million gross proceeds for the company from primary shares; the selling stockholder’s secondary sale generated no proceeds for First Tracks. Stock-based compensation was $28.7 million for the first nine months of 2026.

Clinical developments, outlook and risks

  • ANB033: On October 12, 2026, the company announced positive top-line results from Cohort 1 of its Phase 1b celiac disease trial (32 patients). ANB033 showed statistically significant differences versus placebo on reported histology and symptom endpoints; no serious or severe adverse events or discontinuations were reported in treated patients. Cohort 2 is assessing mucosal healing over 12 weeks. ANB033 has FDA Fast Track designation for celiac disease. A randomized Phase 1b trial in eosinophilic esophagitis is also underway; the company plans Phase 2 development in vitiligo and another indication.
  • Rosnilimab: The company describes positive Phase 2b rheumatoid arthritis results, including statistically significant Week 12 results on the primary DAS28-CRP endpoint across three doses and selected secondary endpoints. It reported deepening or durable responses in the all-active period and generally mild-to-moderate adverse events. The filing also notes that prior ulcerative colitis Phase 2 data were not positive.
  • ANB101: The Phase 1 healthy-volunteer trial, initiated in March 2025, was completed in August 2026. The filing provides no new clinical results for the trial.
  • Management expects significant expenses and operating losses to continue and does not expect product-sale revenue in the near future, if at all. It states available resources are expected to fund the current operating plan for at least 12 months from issuance of the financial statements; this estimate depends on assumptions and development spending.
  • After quarter-end, a private placement closed October 19, 2026, issuing 6,106,870 shares at $32.75 per share for approximately $200 million gross proceeds, before fees and expenses. Resale registration was filed October 26. The financing provides additional capital but dilutes existing holders.
  • Key risks include clinical failure or delay, adverse events, regulatory uncertainty, reliance on contract manufacturers and CROs, supply-chain and trade-policy exposure, competition, intellectual-property protection, and the need for future capital. The company says it may need to raise additional financing; no assurance is given that future funding will be available on acceptable terms.
  • No material legal proceedings are reported. Management concluded disclosure controls and procedures were effective at a reasonable-assurance level; no material changes to internal control over financial reporting were identified during the quarter.

Important facts for investors to verify

  • Final and follow-up ANB033 Cohort 1 data, including sample size, endpoint analyses, safety and whether results are confirmed in Cohort 2 and other indications.
  • Upcoming ANB033 and rosnilimab development milestones, trial timelines, enrollment and expected clinical-development costs.
  • Actual cash burn and runway after the October financing, and how management plans to allocate the approximately $200 million gross proceeds.
  • Share-count dilution from the October placement and outstanding options, RSUs and PSUs; 42,017,901 shares were reported outstanding as of October 29, 2026.
  • Whether standalone operating costs, vendor commitments, manufacturing capacity or financing needs differ materially from the company’s current assumptions.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.